Contemporary Clinical Trials

metrics 2024

Empowering Global Collaboration in Medicine

Introduction

Contemporary Clinical Trials, published by Elsevier Science Inc, stands at the forefront of clinical research, providing a dedicated platform for the dissemination of innovative studies and methodologies in medicine and pharmacology. With an impressive impact factor reflecting its consistent contributions to the field, this journal is categorized in the Q1 quartile for both Medicine (miscellaneous) and Pharmacology (medical) as of 2023. The journal's scope encompasses a broad range of topics pertinent to clinical trial design, execution, and analysis, aiming to enhance the effectiveness and safety of therapeutic interventions. Operating under an Open Access model, it ensures that the latest research is accessible to a global audience, fostering collaboration and discussion among researchers, professionals, and students alike. In publishing high-quality articles since its inception in 2005, Contemporary Clinical Trials continues to shape the future of clinical research with its commitment to excellence and innovation.

Metrics 2024

SCIMAGO Journal Rank0.98
Journal Impact Factor2.00
Journal Impact Factor (5 years)2.10
H-Index75
Journal IF Without Self2.00
Eigen Factor0.01
Normal Eigen Factor1.95
Influence0.92
Immediacy Index0.30
Cited Half Life6.70
Citing Half Life8.90
JCI0.57
Total Documents3012
WOS Total Citations5356
SCIMAGO Total Citations16974
SCIMAGO SELF Citations536
Scopus Journal Rank0.98
Cites / Document (2 Years)2.24
Cites / Document (3 Years)2.34
Cites / Document (4 Years)2.29

Metrics History

Rank 2024

IF (Web Of Science)

MEDICINE, RESEARCH & EXPERIMENTAL
Rank 122/189
Percentile 35.70
Quartile Q3
PHARMACOLOGY & PHARMACY
Rank 222/354
Percentile 37.40
Quartile Q3

JCI (Web Of Science)

MEDICINE, RESEARCH & EXPERIMENTAL
Rank 108/189
Percentile 42.86
Quartile Q3
PHARMACOLOGY & PHARMACY
Rank 210/354
Percentile 40.68
Quartile Q3

Quartile History

Similar Journals

ADVANCES IN THERAPY

Exploring innovative therapies that transform patient care.
Publisher: SPRINGERISSN: 0741-238XFrequency: 12 issues/year

ADVANCES IN THERAPY is a prestigious peer-reviewed journal published by SPRINGER, specializing in the diverse fields of medicine and pharmacology. Established in 1984, this influential journal has become an essential resource for researchers and professionals, boasting a commendable impact factor and categorically ranking within the Q1 quartile in both Medicine (Miscellaneous) and Medical Pharmacology as of 2023. With an impressive Scopus ranking at #52 out of 272 in the realm of medical pharmacology, it places itself in the top 81st percentile, underscoring its importance in advancing therapeutic knowledge and practices. Although the journal is not open access, it provides invaluable insights and the latest research findings in therapies that significantly impact patient care, making it a vital reference for clinicians, academicians, and students alike.

EClinicalMedicine

Elevating knowledge, enhancing patient care.
Publisher: ELSEVIERISSN: Frequency: 12 issues/year

EClinicalMedicine, published by Elsevier, is a leading open-access journal that has been championing the field of medicine since its inception in 2018. With a notable impact factor and a commendable ranking of 16th out of 636 in the category of General Medicine, placing it in the 97th percentile, this journal stands as a pivotal resource for the medical community. The journal encompasses an array of topics within the medicine (miscellaneous) category, fostering interdisciplinary collaboration and advancing research that influences clinical practices worldwide. Researchers, professionals, and students alike can benefit from its robust content, enriched by a Q1 quartile classification in 2023, illustrating its high quality and relevance. As an open-access journal, EClinicalMedicine promotes wider dissemination and accessibility of cutting-edge studies, ensuring that critical findings are available to a global audience. Its address in the United Kingdom positions it at the heart of innovative medical research and practice, making it an excellent platform for those at the forefront of health science advancements.

JACC-Heart Failure

Catalyzing Progress in Heart Failure Research
Publisher: ELSEVIER SCI LTDISSN: 2213-1779Frequency: 12 issues/year

JACC-Heart Failure is a premier journal in the field of cardiology, published by Elsevier Science Ltd, that has rapidly established itself as a vital resource for researchers and practitioners focused on heart failure and cardiovascular health. With an impressive impact factor and ranking in the Q1 category for Cardiology and Cardiovascular Medicine, this journal is recognized for its high-quality peer-reviewed articles that contribute significantly to advancements in clinical practice and scientific understanding of heart failure. As of 2023, the journal ranks #10 out of 387 in its field, positioning it in the 97th percentile of Scopus rankings, which highlights its influential role in disseminating cutting-edge research. Although the journal does not operate under an open-access model, it maintains a rigorous review process, ensuring the publication of articles that are both innovative and clinically relevant. Targeting an audience of dedicated researchers, healthcare professionals, and students, JACC-Heart Failure serves as an essential platform for exploring the complexities of heart failure treatments, management strategies, and future directions in cardiology.

Therapeutic Innovation & Regulatory Science

Pioneering Research for Tomorrow's Therapeutic Landscape
Publisher: SPRINGER HEIDELBERGISSN: 2168-4790Frequency: 6 issues/year

Therapeutic Innovation & Regulatory Science, published by Springer Heidelberg, is an esteemed journal that focuses on the intersection of therapeutic innovations and the regulatory frameworks that govern them. Established in 1970 and continuing its legacy of excellence through converged years, this journal plays a crucial role in supplying cutting-edge research, reviews, and discussions that advance understanding in the fields of pharmacology and healthcare regulation. With an impact factor reflective of its rigorous peer-review standards, this journal holds a prestigious Q1 ranking in Pharmacology, Toxicology, and Pharmaceutics (Miscellaneous) for 2023, reflecting its influence and the high quality of its published material. The journal's wide scope also embraces public health and environmental studies, making it an essential resource for researchers and professionals navigating these critical areas. Open access options enhance its visibility and accessibility, ensuring that the latest discoveries and regulatory insights are readily available to a global audience. For those at the forefront of medicinal science and regulatory affairs, Therapeutic Innovation & Regulatory Science is your avenue to understanding pivotal innovations that shape contemporary therapeutic practices.

JAMA Ophthalmology

Exploring Innovations for Visionary Outcomes
Publisher: AMER MEDICAL ASSOCISSN: 2168-6165Frequency: 12 issues/year

JAMA Ophthalmology, the premier journal in the field of ophthalmology, is published by the esteemed American Medical Association. Renowned for its rigorous peer-review process and commitment to advancing eye health research, JAMA Ophthalmology holds a prestigious position in the scientific community, boasting an impressive impact factor and ranking as Q1 in the category of Ophthalmology. With a Scopus rank of #3 out of 137 in its field and a remarkable 98th percentile, the journal serves as an invaluable resource for researchers, healthcare professionals, and students dedicated to the ophthalmic sciences. Readers can explore a wealth of cutting-edge findings, clinical studies, and review articles that not only contribute to the sustainable advancement of ophthalmic knowledge but also foster innovative approaches in patient care. As we converge into 2024, the journal continues to embrace open access principles, ensuring that groundbreaking research is readily available to a global audience, enhancing collaborative efforts and furthering the development of the ophthalmology discipline.

PANMINERVA MEDICA

Advancing medical knowledge since 1959.
Publisher: EDIZIONI MINERVA MEDICAISSN: 0031-0808Frequency: 4 issues/year

PANMINERVA MEDICA is a distinguished journal published by EDIZIONI MINERVA MEDICA, focusing on the multifaceted field of medicine since its inception in 1959. With an ISSN of 0031-0808 and an E-ISSN of 1827-1898, this journal is esteemed for its rigorous peer-review process and its contribution to clinical and experimental research across various domains of medicine. Based in Italy, it holds a commendable position in the 2023 Scopus rankings, where it is placed in the 84th percentile among general medicine journals, highlighting its relevance and scholarly impact. As a Q3 category journal in the medicine (miscellaneous) quartiles, PANMINERVA MEDICA is committed to disseminating high-quality research, fostering scientific dialogue, and advancing medical knowledge globally. While currently not offering open access, it serves as a vital resource for researchers, practitioners, and students seeking to stay at the forefront of medical advancements. The journal is poised to continue its tradition of excellence as it converges into 2024, ensuring robust discourse in healthcare and clinical practices.

DIABETES CARE

Empowering innovation in diabetes care and management.
Publisher: AMER DIABETES ASSOCISSN: 0149-5992Frequency: 12 issues/year

DIABETES CARE, published by the American Diabetes Association, is a premier journal dedicated to advancing the understanding and management of diabetes and related metabolic disorders. Since its inception in 1978, this journal has maintained a commitment to disseminating high-quality research, evidenced by its prestigious ranking in the Q1 category across multiple fields including Advanced and Specialized Nursing, Endocrinology, Diabetes and Metabolism, and Internal Medicine. With an impressive impact factor and distinguished Scopus rankings, DIABETES CARE serves as an essential resource for researchers, clinicians, and students alike, facilitating the exchange of knowledge and fostering innovation in diabetes care. Although not an open-access publication, the journal offers various ways to access groundbreaking studies and advancements in the field. This commitment to excellence reflects the journal's vital role in shaping diabetes research and clinical practices globally.

Addiction Science & Clinical Practice

Championing open access to addiction research and practice.
Publisher: BMCISSN: 1940-0640Frequency: 1 issue/year

Addiction Science & Clinical Practice is a premier open-access journal dedicated to advancing the understanding and treatment of addiction through evidence-based research and clinical practice. Published by BMC in the United Kingdom since 2007, this journal has significantly impacted the fields of Clinical Psychology, Medicine, and Psychiatry and Mental Health, proudly securing a Q1 ranking in multiple categories as of 2023. With an emphasis on high-quality research, the journal provides an inclusive platform for the dissemination of innovative findings and clinical insights that address the complexities of addiction. Researchers, practitioners, and students alike benefit from its unrestricted access since 2012, allowing for widespread dissemination of knowledge. Located at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to lead the way in fostering collaboration and informing best practices in addiction science.

Pilot and Feasibility Studies

Transforming preliminary insights into impactful healthcare solutions.
Publisher: BMCISSN: Frequency: 1 issue/year

Pilot and Feasibility Studies, published by BMC, stands at the forefront of innovative research in the realm of pilot studies and feasibility assessments, serving as a vital resource for researchers in medicine and healthcare. As an Open Access journal since 2015, it provides unrestricted access to its content, promoting the dissemination of significant findings and fostering collaboration among the global research community. Based in the United Kingdom, this journal has solidly established its reputation, ranking in the Q2 quartile for medicine (miscellaneous) in 2023 with a Scopus rank of #183 out of 398, placing it within the 54th percentile. The journal's scope encompasses a wide range of methodologies and applications, encouraging the translation of pilot studies into viable healthcare practices. With a commitment to quality and accessibility, Pilot and Feasibility Studies plays an essential role in enhancing the rigor and impact of preliminary research, ultimately contributing to the advancement of medical science.

BEHAVIORAL MEDICINE

Innovating Approaches to Behavioral Health
Publisher: ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTDISSN: 0896-4289Frequency: 4 issues/year

Behavioral Medicine is a distinguished journal published by Routledge Journals, Taylor & Francis Ltd, specializing in the critical intersection of behavior, health, and disease. Established in 1988, this quarterly academic journal has continually evolved, contributing to the growing understanding of how psychological, behavioral, and social factors impact health outcomes. With an impressive impact factor and consistent categorization in the Q2 quartile for both Applied Psychology and Psychiatry and Mental Health, it stands at the forefront of its field, ranking #182 out of 567 in Psychiatry and #83 out of 249 in Applied Psychology. Behavioral Medicine is committed to advancing research that bridges gaps between psychological theory and medical practice, making it essential reading for researchers, healthcare professionals, and students alike. All articles are accessible in print and online, offering numerous pathways for engagement with this vital field.